ADMA Biologics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026Shows how much money the company made and spent in the three months ending June 30, 2026.
Shows how much money the company made and spent in the three months ending March 31, 2026.
The drug can now be used for more patients (ages 2+), which could increase sales and help more people.
Shareholders voted to keep leadership and chose KPMG LLP as the auditor to check the company's money.
Stocky reads ADMA Biologics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
ADMA Biologics, Inc.'s most recent tracked filing was a 10-Q on 5 Aug 2026: Second quarter 2026 financial results announced.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.